HIV Knowledge Network Study Group

Estimated time to complete activity: 1 hour

This Webcast requires a broadband Internet connection and Flash Player 8 or greater. (Optional) Sound card and speakers for audio

This activity is jointly sponsored by the Postgraduate Institute for Medicine and HealthmattersCME
This activity is supported by an educational grant from Bristol-Myers Squibb

Target Audience

This activity has been designed to meet the educational needs of physicians involved in the care of patients with HIV

Program Overview

There are currently more than 1.2 million people living with the human immunodeficiency virus (HIV) in the United States, with more than 40,000 new infections annually. The understanding and management of HIV disease is constantly evolving. HIV researchers and providers attend or monitor scientific conferences to improve their understanding and refine their treatment strategies for HIV diagnosis and management. Similar to practices in other therapeutic areas, whenever possible, clinical findings, research, and understanding of HIV disease are immediately applied to clinical practice.

The HIV Knowledge Network Study Group will synthesize the key clinical data presented at the XVII International AIDS Conference, held in Mexico City, August 3-8, 2008, and provide expert commentary on their clinical significance.

Educational Objectives

Upon completion of this activity, participants should be able to:

• Explain how newly presented study results in antiretroviral therapy apply to clinical practice

• Review significant developments and strategies in antiretroviral therapy as they relate to treating naïve patients, patients in second-line and later regimens, and multiclass-experienced patients

• Describe recent antiretroviral complications, including their potential impact on treatment strategies and HIV management

Faculty

Program Moderator
W. David Hardy, MD
Director, Division of Infectious Diseases
Cedars-Sinai Medical Center
Associate Professor of Medicine-in-Residence
David Geffen School of Medicine at UCLA
Los Angeles, CA

Charles B. Hicks, MD
Associate Professor of Medicine
Associate Director, Duke AIDS Research and Treatment Center
Duke University Medical Center
Durham, NC

Sally Hodder, MD
Professor of Medicine
New Jersey Medical School
University of Medicine and Dentistry of New Jersey
Newark, NJ

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and HealthmattersCME. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

W. David Hardy, MD
• Grant/Research Support: Pfizer, Tibotec, GlaxoSmithKline, Bionor
• Consultant: Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Merck, Tibotec, GlaxoSmithKline
• Speakers Bureau: Pfizer, Merck, Tibotec

Charles B. Hicks, MD
• Consultant: Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Gilead, Inc., Merck, Tibotec, Monogram Biosciences, Boehringer Ingelheim
• Speakers Bureau: Merck

Sally M. Hodder, MD
• Grant/Research Support: Tibotec, Bristol-Myers Squibb, Gilead, Inc.
• Scientific Advisory Board: Tibotec, Bristol-Myers Squibb, Gilead, Inc, Boehringer Ingelheim
• Speakers Bureau: Bristol-Myers Squibb

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Linda Graham, RN, BSN, BA (PIM)
• No financial interest/relationships with commercial interests relating to the topic of this activity

Jan Hixon, RN, BSN, MA (PIM)
• No financial interest/relationships with commercial interests relating to the topic of this activity

Trace Hutchison, PharmD (PIM)
• No financial interest/relationships with commercial interests relating to the topic of this activity

James Murphy (HealthmattersCME)
• No financial interest/relationships with commercial interests relating to the topic of this activity

Method of Participation
There are no fees for participating and receiving CME credit for this activity. During the period October, 2008 through October, 2009, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the posttest by recording the best answer to each question in the answer key on the evaluation form; 4) complete the evaluation form; and 5) mail or fax the evaluation form with answer key to Postgraduate Institute for Medicine.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be mailed to you within 3 weeks.

Media
Internet Activity

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), HealthmattersCME, and Bristol-Myers Squibb do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, HealthmattersCME, and Bristol-Myers Squibb. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.